Objective Early results of a randomised trial showed reduced fibrosis due to recurrent HCV hepatitis with tacrolimus triple therapy (TT) versus monotherapy (MT) following transplantation for HCV cirrhosis. We evaluated the clinical outcomes after a median 8 years of follow-up, including differences in fibrosis assessed by collagen proportionate area (CPA).
Design 103 consecutive liver transplant recipients with HCV cirrhosis receiving cadaveric grafts were randomised to tacrolimus MT (n=54) or TT (n=49) with daily tacrolimus (0.1 mg/kg divided dose), azathioprine (1 mg/kg) and prednisolone (20 mg), the last tailing off to zero by 6 months. Both groups had serial transjugular biopsies with hepatic venous pressure gradient (HVPG) measurement. Time to reach Ishak stage 4 was the predetermined endpoint. CPA was measured in all biopsies. Factors associated with HCV recurrence were evaluated. Clinical decompensation was the first occurrence of ascites/hydrothorax, variceal bleeding or encephalopathy.
Results No significant preoperative, peri-operative or postoperative differences between groups were found. During 96 months median follow-up, stage 4 fibrosis was reached in 19 MT/11 TT with slower fibrosis progression in TT (p=0.009). CPA at last biopsy was 12% in MT and 8% in TT patients (p=0.004). 14 MT/ three TT patients reached HVPG≥10 mm Hg (p=0.002); 10 MT/three TT patients, decompensated. Multivariately, allocated MT (p=0.047, OR 3.23, 95% CI 1.01 to 10.3) was independently associated with decompensation: 14 MT/ seven TT died, and five MT/ four TT were retransplanted.
Conclusions Long term immunosuppression with tacrolimus, azathioprine and short term prednisolone in HCV cirrhosis recipients resulted in slower progression to severe fibrosis assessed by Ishak stage and CPA, less portal hypertension and decompensation, compared with tacrolimus alone.
ISRCTN94834276 —Randomised study for immunosuppression regimen in liver transplantation.
- LIVER TRANSPLANTATION
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
Statistics from Altmetric.com
Significance of this study
What is already known on this subject?
Immunosuppression worsens severity of recurrence of HCV after liver transplantation.
There are very few studies and only one randomised study assessing immunosuppressive protocols on different severity of recurrence of chronic HCV hepatitis.
What are the new findings?
Triple therapy with tacrolimus, azathioprine and tapering steroids resulted in less fibrosis progression compared with tacrolimus monotherapy, contrary to the initial hypothesis, that less immunosuppression should reduce progression of HCV recurrent disease.
Triple therapy also resulted in less progression of clinically significant portal hypertension (hepatic venous pressure gradient ≥10 mm Hg) and less clinical decompensating events (ascites, bleeding, varices, encephalopathy).
Discontinuation of azathioprine resulted in further fibrosis progression compared with continuation of azathioprine.
The fibrosis progression with triple therapy is the lowest recorded in the literature.
How might it impact on clinical practice in the foreseeable future?
This trial obliges a review of immunosuppressive protocols in patients transplanted with HCV cirrhosis. The use of azathioprine should be considered.
Azathioprine and other immunosuppressive agents need to be tested in HCV replicon systems to assess if there is a direct antiviral effect and in cell systems for any potential immunological interaction with profibrotic and antifibrotic mechanisms.
We published early results of a randomised trial in liver transplant recipients with HCV cirrhosis assessing tacrolimus monotherapy (MT) versus tacrolimus, azathioprine and prednisolone triple therapy (TT), which showed a slower onset of histological severe fibrosis and portal hypertension in the TT arm compared with tacrolimus alone, independent of other factors known to affect fibrosis.1 This was contrary to the starting hypothesis that the lesser immunopotency with MT should result in less fibrosis.
However, despite our initial trial results and other consistent data with more patients,2–4 including a possible benefit with azathioprine,5 the optimal immunosuppression for HCV transplant recipients is still debated.6 Indeed, immunosuppression worsens the severity of HCV recurrence.6 Cyclosporine has no advantage versus tacrolimus regarding stage progression7 despite in vitro (but not in vivo) activity against HCV.8 Tacrolimus compared with cyclosporine improves both patient and graft survival including patients transplanted for hepatitis C cirrhosis6 and is the preferred calcineurin inhibitor.
Therefore, we evaluated outcomes in our trial, after a median of 8 years of follow-up, including the original end points as well as differences in hepatic venous pressure gradient (HVPG) and collagen proportionate area (CPA) as a quantitative measure of fibrosis and clinical decompensation.
Patients and methods
Inclusion—exclusion criteria, randomisation and endpoints
From January 2000 to June 2007, at the Royal Free Hospital, consecutive transplant recipients were randomised if they had cirrhosis, were HCV RNA positive in serum and previous histology was compatible with HCV liver disease. Randomisation at the Royal Edinburgh Infirmary and St Vincent's University Hospital was between 12/2003 and 5/2006. Inclusion and exclusion criteria were published previously.1 The study protocol was approved by the Hospital Ethics committees at each site.
Follow-up stopped at death, retransplantation or 1/2013. We analysed the original primary endpoints—progression to Ishak stage 4 and graft failure either resulting in retransplantation or patient's death. We also evaluated patients’ survival, acute cellular rejection episodes, chronic rejection, recurrence of HCV (defined by Ishak inflammation score≥4), HVPG progression to 10 mm Hg, CPA, fibrosis progression assessed by CPA and Ishak stage (for comparison with other published studies), and time to first episode of clinical decompensation defined as whichever occurred first, of ascites/hydrothorax, variceal bleeding or encephalopathy.
For each patient, the following were evaluated: demographic and clinical data (including concomitant hepatocellular carcinoma (HCC) and/or alcoholic aetiology), donor age/gender, cold/warm ischaemia time, initial immunosuppression and subsequent changes, occurrence and treatment of rejection episodes, cytomegalovirus or other infections, histological episodes of de novo hepatitis, genotype, viral load pre-LT and 1 year post-liver transplantation (LT), antiviral treatment and sustained virological response (SVR), diabetes mellitus pretransplant and post-transplant, human leucocyte antigen and blood group compatibility of donor/recipient, sex match/mismatch and tacrolimus levels at 5, 15 and 30 days post-LT.
The MT group received tacrolimus 0.1 mg/kg/day (two divided doses). The TT group received the same tacrolimus dosing, together with azathioprine—initially intravenously then orally—1 mg/kg/day, and methylprednisolone (16 mg/day intravenous) until oral intake was established (20 mg/day prednisolone). Tacrolimus trough concentrations were evaluated on alternate week days. The doses were adjusted to maintain a whole blood level within 5–14 ng/mL (aiming for 5–10). Azathioprine was continued at the same starting dose unless neutropenia developed: 16 patients discontinued azathioprine between 10 and 37 months (median 14 months) post-LT. Prednisolone was gradually tapered from 3 weeks onwards and then stopped between 3 and 6 months, according to each centre's practice. Protocol biopsies were undertaken to diagnose acute cellular rejection between days 5 and 10. If moderate or severe rejection was diagnosed, daily intravenous 1 gm methylprednisolone was given for 3 days.9
Determination of HCV genotype was performed by reverse transcription PCR and reverse hybridisation assay of the amplified sequence (InnoLipa HCV II, Innogenetics, Zwijnaarde, Belgium).10
Qualitative tests were performed by a reverse transcription PCR assay (Amplicor HCV, Roche Diagnostic Systems Inc, Branchburg, New Jersey, USA—later Bayer Thermomechanical Analyzer Component system, Berkeley, California, USA).11
Protocol liver biopsies were performed at yearly intervals and also if clinically indicated. All liver biopsies were reviewed by liver trained histopathologists in each centre, in a blinded fashion.
Liver biopsy samples were formalin fixed, paraffin embedded and stained with H&E, Gordon and Sweet staining was used for reticulin and Sirius red and Van Gieson stains were used in Edinburgh. All biopsies at the Royal Free Hospital were restained with picroSirius Red to ensure comparable staining for collagen quantification and determination of CPA by digital image analysis. The stage of disease (fibrosis 0–6) and the grade of necroinflammatory activity were evaluated according to Ishak et al.12
The number of liver cores, length of biopsy (lengths of each core summed), and portal tract number per core and in total were recorded.13 Liver biopsies<12 mm long were excluded (29 of 310). Complete portal tracts were defined according to Crawford and colleagues.14 The equipment used and CPA measurement were performed as previously described.15
Acute cellular rejection was graded using the Royal Free Hospital score.16 Histological de novo hepatitis (HDNH) C termed ‘histological acute hepatitis C’ previously1 ,2 was defined as before as an increase in alanine aminotransferase levels (>2 upper normal limit), together with histological changes consistent with hepatitis without diagnostic features of cellular rejection, duct loss or other cause of liver injury, including alloimmune hepatitis (autoantibodies negative).2
Fibrosis progression in each patient was calculated by percentage change of fibrosis according to CPA (CPA in latest biopsy subtracted from CPA at 1 year post-LT, divided by time in years between the two biopsies: CPA%/year). Ishak stage progression was calculated as in latest biopsy subtracted from stage in the biopsy at 1 year, divided by time in years—stage ‘units’/year between the two biopsies.
Results are expressed as median and ranges. Categorical variables were compared using the χ2 or Fisher's exact tests. Continuous variables were compared by Student t test, or if not normally distributed by the Mann–Whitney test. We compared the two randomised groups for histological, virological and clinical outcomes in a preplanned evaluation.
Statistical comparison was made by life tables (Kaplan–Meier) and log rank testing. All the following variables associated with HCV recurrence in the literature (table 1)—except IL28B—were evaluated in the Cox regression analysis: donor age/gender, cold/warm ischaemia time, initial and changes in immunosuppression occurrence and treatment of rejection episodes, cytomegalovirus or other infection, HDNH episodes, genotype, viral load pre-LT and 1 year post-LT, antiviral treatment and SVR, diabetes mellitus pre-LT and post-LT, human leucocyte antigen and blood group compatibility of donor/recipient, sex match/mismatch and tacrolimus levels at 5/15/30 days post-LT.
A p value<0.05 was considered statistically significant. SPSS V.20.0 was used.
Patients were censored at the time of SVR, when analysing progression to HVPG≥10 mm Hg, to CPA cut-offs of 6% and 7.2%, to first clinical decompensation event, and survival. As reported previously, sample size was calculated to be 110 patients: S4 was estimated to occur in 35% by 3 years with a projected decrease to 10% with tacrolimus MT, and this required a sample size of 99. Considering a dropout rate of 10% (including early deaths), we concluded that 110 patients would be needed with a two-tailed test with significance at 5% and a power of 80% (1-B).17
Patients’ demographic and transplant data
A total of 103 patients (89 Royal Free Hospital, eight Royal Edinburgh Infirmary and six St Vincent's Hospital) were randomised as previously documented:1 29 women, 74 men; 30 had HCC and 22 concomitant alcoholic liver injury. In the last follow-up, there were only two alcohol relapsers, one in each randomised arm. Two patients were coinfected with hepatitis B or D virus (remained HBV–DNA negative in blood throughout the study).
By randomisation, 54 received MT and 49 TT. The groups were well matched at randomisation with no significant differences in preoperative, peri-operative or immediately postoperative variables: four were retransplanted early post-LT, two for hepatic artery thrombosis and one for primary non-function in the MT group; and one TT for hepatic artery thrombosis. Two MT patients were withdrawn within the first month post-LT because of side effects of treatment.
We analysed the remaining 97: 49 MT and 48 TT. Median follow-up was 96 months (range 1–146): 91.6 months MT and 98.7 months TT; 15/97 (15.5%) died within 3 years from randomisation. In all, 78/97 (80%) had a follow-up of more than 3 years, fulfilling the sample size calculation based on Log rank testing.
Clinical characteristics were well balanced and HCV genotypes were similarly distributed. In tacrolimus MT: 20 patients genotype 1 (41%), seven genotype 2 (14%), 16 genotype 3 (33%) and six genotype 4 (12%). In TT group, the distribution was 20 patients genotype 1 (41%), one genotype 2 (2%), 19 genotype 3 (40%), seven genotype 4 (15%) and genotype 5 (2%).
Median HCV RNA levels were not significantly different, pretransplant or at 1 or 3 months post-LT.1 Antiviral treatment for HCV recurrence was used in 25 of 30 patients reaching stage 4 (19 MT, 11 TT), with six achieving SVR (18, 36 and 52 months MT; 36, 38 and 40 months TT). The median time to initiate therapy was the same in the two trial arms: 45 months for 19 MT patients and 51 months for 11 TT patients. All patients were treated with pegylated interferon α-2b 0.5 μg/kg weekly escalating to 1 μg/kg, and ribavirin 200 mg escalating to 800 mg/daily. The HDNH episodes were only diagnosed within 6 months post-LT, and occurred in 17 MT and eight TT patients.
Tacrolimus trough levels were a median of 7.7 ng/mL (MT) and 5 ng/mL (TT) (p=0.03) at 5 days; 8.5 ng/mL (MT) and 6.1 ng/mL (TT) (p=0.017) at 15 days post-LT; and 7.9 ng/mL (MT) and 6.7 ng/mL (TT) (p=0.031) at 30 days post-LT. The difference in median tacrolimus levels was maintained up to 6 months post-LT: 7 ng/mL in MT group versus 5.8 ng/mL in TT arm (p=0.044). There was no difference at 1 year post-LT. The median tacrolimus levels at 1 year post-LT were not significantly different between those who discontinued azathioprine before 1 year post-LT (7.7 ng/mL) versus those who were still on azathioprine at that point (6.7 ng/mL).
There were no new rejection episodes compared with those previously published:1 ,9 During the first 3 months, 22 MT had 42 rejection episodes and 16 received 21 courses of methylprednisolone. In comparison, 31 TT had 64 rejection episodes and 24 received 30 courses of methylprednisolone. It should be noted that after the last bolus, steroid dosage (if in TT arm) reverted to 20 mg/day (ie, no high to low tail off of oral steroids) or none in MT arm.
The proportion of patients whose serum creatine rose to≥130 µmol/L (1.5 mg/dL) during the first 3 months post-transplant was similar: 23% MT versus 20% TT. At the last follow-up, abnormal serum creatine (>1.5 mg/dL) was noted in nine out of 37 (24%) patients alive in the MT and five out of 41 (12%) patients alive in TT group. No patient has ended up on dialysis. Incidence of diabetes post-LT was 33% MT and 31% TT.
There was no difference in numbers of biopsies and average number of biopsies/patient performed between groups. Patients’ characteristics are shown in table 2. The number of patients with suitable biopsies evaluated for Ishak staging was 90/97 (45 MT/45 TT) and for CPA was 81/89 Royal Free patients (37 MT/44 TT).
Factors associated with reaching Ishak stage 4 or greater
At least stage 4 was reached by 19 MT patients at a median of 32 months: eight reached stage 4, eight stage 5 and three stage 6. Correspondingly, 11 TT patients reached stage 4 or greater at a median of 49 months (six reached stage 5, none stage 6). Patients receiving antiviral treatment or achieving SVR were not censored as treatment in all patients was initiated after reaching Ishak stage 4 or greater. In univariate and multivariate analyses, three factors were associated with fibrosis stage ≥4: randomisation to allocated MT treatment (p=0.001, OR 2.94, 95% CI 1.3 to 6.7), HDNH (p=0.015, OR 2.67, 95% CI 1.23 to 5.8) and discontinuation of azathioprine (p=0.036, OR 2.24, 95% CI 1.3 to 3.9). Patients who died without reaching stage 4 (four MT, one TT) were censored at the last biopsy with its Ishak stage. Hazard curves of MT/TT allocation (p=0.005 Mantel–Cox) and use/discontinuation of azathioprine (p=0.003 Mantel–Cox) are shown in figure 1.
Factors associated with CPA cut-offs
As previously published, CPA of 6% at 1 year biopsy post-LT was highly predictive of clinical outcome in a larger recurrent HCV population after liver transplantation3 and CPA of 7.2% was independently associated with portal hypertension, that is, HVPG ≥6 mm Hg.15 We used the cut-off of 6% of CPA and the time to first reach CPA≥6% to compare the allocated treatments, including a multivariate analysis: 20 MT patients reached CPA≥6% (20/37 or 54%) at a median of 41 months, while 13 TT reached CPA≥6% (13/44, 30%) at a median of 49 months. In the multivariate analysis, allocated treatment with MT (p=0.007, OR 2.67, 95% CI 1.31 to 5.46) and HDNH (p=0.001, OR 3.27, 95% CI 1.61 to 6.6) were independently associated with CPA≥6%. For CPA≥7.2%, allocated MT treatment (p=0.004, OR 2.85, 95% CI 1.38 to 5.86), HDNH (p=0.006, OR 2.69, 95% CI 1.32 to 5.48) and discontinuation of azathioprine (p=0.011, OR 2.1, 95% CI 1.1 to 2.8) were independent factors. Hazard curves are shown in figure 2 for CPA cut-offs of 6% and 7.2% (p=0.002 and p=0.001 Mantel–Cox respectively).
Factors associated with portal hypertension
HVPG measurement was performed combined with transjugular biopsies in 33 MT and 31 TT patients. These represent 78% MT and 72% TT patients surviving at 1 year at the Royal Free Hospital as HVPG was not measured in Edinburgh or Dublin. There were 154 HVPG measurements post-LT: 64 at a median of 17 months, 41 at a median of 31 m, 30 at a median of 48 m, 15 at a median of 63 m and four at a median of 86 m. HVPG≥10 mm Hg (clinically significant portal hypertension) was reached in 11 MT compared with four TT patients. Cox regression analysis revealed HDNH (p=0.015, OR 3.68, 95% CI 1.26 to 10.69) and allocated MT treatment (p=0.017, OR 4.13, 95% CI 1.28 to 13.29) to be independently associated with HVPG≥10 mm Hg: hazard curves are shown in figure 3 (p=0.027 Mantel–Cox and 0.019 Breslow).
Factors associated with clinical decompensation
Decompensation occurred in 13 patients (all reached stage 5/6 at the time of decompensation) at a mean of 82 months: nine MT patients (seven ascites, one variceal bleeding, one encephalopathy) at a mean of 70 m and four TT patients (three ascites, one encephalopathy) at a mean time of 91 m. Hazard curves are shown in figure 3 (p=0.015 by Mantel–Cox, 0.037 Breslow).
In the Cox regression analysis, allocated MT treatment was the only statistically significant factor associated with clinical decompensation (p=0.047, OR 3.23, 95% CI 1.01 to 10.3).
Fibrosis progression rate
We evaluated 310 biopsies for Ishak stage and 289 biopsies for CPA due to inadequate material for restaining. The number of biopsies performed every year were: 74 in year 1 (34 MT/40 TT), 57 in year 2 (27 MT/30 TT), 53 in year 3 (26 MT/27 TT), 36 in year 4 (17 MT/19 TT), 34 in year 5, (18 MT/16 TT), 27 in year 6 (14 MT/13 TT), 21 in year 7 (11 MT/10 TT), 18 in year 8 (9 MT/9 TT), 4 in year 9 (2 MT/2 TT) and 5 in year 10 (3 MT/2 TT). Fibrosis progression according to CPA and stage progression over time are shown in figure 4. Median CPA fibrosis progression rate was 0.7%/year (0.74%/year MT, 0.67%/year TT). Mean stages per year (given for comparison with published studies) were: at 1 year (1.45), 2 years (2.1), 3 years (2.38), 4 years (2.86), 5 years (3), 6 years (3.2), 7 years (3.2) 8 years (3.47), 9 years (4) and 10 years (5). Mean stages for MT group were: 1.58, 2.37, 2.77, 3.18, 3.28, 3.66, 3.22, 4, 5 and 5, and for TT group were: 1.3, 1.9, 2, 2.57, 2.6, 2.77, 3, 2.87, 3 and 3 for years 1–10 post-LT respectively. Mean Ishak stage progression rate was 0.2 stage U/year (0.3 stage U/year in MT, 0.2 stage U/year TT).
Fibrosis progression rate was not significantly different between patients requiring steroids boluses for acute cellular rejection or not. Median CPA fibrosis progression rate was 0.72%/year in those requiring steroids boluses and 0.69%/year in those not treated for acute cellular rejection. Mean Ishak stage progression rate was 0.2 stage U/year in both groups.
Factors associated with early survival overall survival and graft survival
In the TT group three patients died within 3 months: one patient after retransplant (sepsis—2 days) and two at 1 month from sepsis and multiple organ failure. There were another four deaths: one due to non-liver related causes at 6 months, two from recurrent HCV disease (30 and 42 months) and one at 95 months from recurrent HCC.
In the MT group, 14 patients died: five from sepsis and multiple organ failure (0.3, 0.3, 0.6, 1 and 4 months), one from graft failure (0.5 months), one from pulmonary hypertension (0.2 months), one from ductopenic rejection (18 months) and one from recurrent HCV disease (30 months). Six more patients died in the current update: three from recurrent HCV disease (36, 37 and 72 months post-LT), one from embolic stroke (56 months) and one from lung adenocarcinoma (96 months).
Overall, mortality in the randomised 103 patients favoured TT patients (p=0.036) as well as the 97 currently evaluated (p=0.025). However, there was no statistically significant factor associated with mortality in the multivariate analysis, and no significant difference in deaths due to HCV recurrence.
Similarly, graft survival favoured the TT arm (p=0.019): 15 MT and seven TT patients died, and five MT/4 TT were retransplanted, but this difference was not due to recurrent disease.
In this final evaluation of our randomised study,1 the median follow-up was just over 8 years, the longest published to date following liver transplantation in a randomised trial concerning HCV cirrhosis,6 ,18 and given the numbers who either died within 3 years or survived more than 3 years (used for sample size calculation), this allowed a robust evaluation of clinical outcomes of recurrent HCV disease. Our outcomes included first clinical decompensation event (evaluated for the first time), HVPG and fibrosis progression defined by CPA and Ishak stage.
Fibrosis progression after liver transplantation for hepatitis C related cirrhosis has been studied several times19–24 mainly by assessing changes in Ishak/Metavir scores. Fibrosis progression is well recognised to have prognostic significance before25 and after transplantation.4 The overall rate of increase of disease stage described by changes in Ishak staging in our total trial population is similar or lower than fibrosis rates previously described.22–24 The mean fibrosis Ishak stage was 1.45 and 2.1 in years 1 and 2 post-LT in our whole cohort, and 1.3 and 1.9 at years 1 and 2 post-LT respectively for the TT group, which are as low as those recently published in patients receiving sirolimus (which may have antifibrotic properties) compared with historical controls (0.62 and 1.15 metavir in year 1 and 2 biopsies, respectively).26
The relatively low overall rate of increase of disease stage in our trial population most likely reflects use of combined therapy of tacrolimus with azathioprine and steroids and/or the generally lower trough levels of tacrolimus achieved.2 Since our first publication, we have shown that CPA assessment in HCV post-LT patients correlates with both Ishak stage scores and HVPG, with greater percentage changes in CPA, compared with HVPG in early portal hypertension.15 Moreover, CPA at 1 year biopsy post-LT is highly predictive of clinical outcome in HCV transplanted patients and better than Ishak stage or HVPG.3 In the current update, MT and HDNH were independently associated with reaching CPA cut-offs of 6%3 and 7.2%, the latter corresponding to HVPG≥6 mm Hg,15 reinforcing both the value of CPA and validating these cut-offs as endpoints.27
As in our first publication,1 outcomes favouring the TT group are supported by HVPG measurements.28 There was more clinically significant portal hypertension (associated with advent of complications and worse survival)29 in the MT group (11 patients reached HVPG≥10 mm Hg, compared with four TT) corroborating the more severe fibrosis found in MT patients.
A limitation in this study could be the lack of evaluation of recipient IL28B polymorphism, which was also missing in the recent sirolimus study.26 Some studies suggest a higher recurrence rate of HCV hepatitis with the poor interferon response allele of IL28B in the recipient.31 ,32 However, randomisation will most likely have balanced out the more favourable polymorphism, which in any case is under represented in liver transplant populations.32 Moreover, IL28B was not significantly associated with either overall or liver related mortality in one study,32 and there has been a selection bias in most studies, as only patients with biopsies were evaluated, that is, not every patient with recurrent hepatitis C was biopsied.31 Moreover, no study evaluated immunosuppression when analysing severity of recurrence.31–35 Last, some studies do not show an association of recipient IL28B with worse HCV disease recurrence.36
Our TT group received azathioprine, which many centres have substituted with mycophenalate which however may worsen fibrosis progression compared with azathioprine.5 In addition, low dose maintenance steroids may also favour less severe recurrence and improve graft survival.37–39 However, the use of steroids in transplantation for HCV cirrhosis remains an unresolved issue.6 Interestingly, although steroids boluses greatly increase HCV RNA levels,40 our TT group had more rejection episodes treated with high dose steroids,9 so it may be that the long term benefit of immune modulation with steroids is more important than the risk of HCV activation following steroid boluses for rejection. Indeed, a recent study has shown no distinct advantage of steroid avoidance18 and another group have shown that steroid-free immunosuppression leads to a higher rate of chronic rejection.41
In conclusion, long term maintenance immunosuppression with tacrolimus, azathioprine and shorter term prednisolone in HCV cirrhosis recipients resulted in a slower onset of histological severe fibrosis confirmed by Ishak stage and CPA, less portal hypertension, and less clinical decompensation compared with tacrolimus alone. Our results support and extend our initial report.1 Given that our TT arm has the lowest fibrosis progression rate published so far—lower than sirolimus—26 and that there is some evidence that azathioprine is better than mycophenalate,5 our TT regimen could be considered as a first choice for patients transplanted for HCV cirrhosis, until other evidence proves otherwise.
Competing interests AKB and APD have an unrestricted educational grant from Pfizer.
Ethics approval The hospital ethics committees at each site.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.